EPO and chronic progressive multiple sclerosis: The fact that EPO treatment leads to temporary shifts in iron stores, and upon longterm application causes a picture similar to that of true iron deficiency, as reported in chronic progressive multiple sclerosis (Ehrenreich et al. 2007a), might even provide additional benefit for COVID-19 patients, adding to the panel of protective effects of this growth factor.